Ask AI

Case Challenge: Brain Metastases After Declining Adjuvant Therapy for HER2+ Breast Cancer

Case Challenge
Case Challenge Start Activity
This activity is available for 0.50 CME/CE credit(s).

Released: November 17, 2026

Expiration: May 16, 2027

See Activity Collection

Recent advances in systemic treatment for HER2-positive metastatic breast cancer now require more nuanced approaches to treatment selection and sequencing. This patient case challenges you to navigate clinical decision-making according to patient-specific clinical presentation, including presence of brain metastases, management through treatment-related adverse events, considerations for altering ongoing treatment for those with complete responses to frontline treatment, and currently available evidence.

Patient Case HER2 Pos MBC Brain Mets

Pre Assessment

Assess your current knowledge and clinical approach before beginning your Case Challenge.
1.

How many people with breast cancer do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 58-year-old woman is newly diagnosed with HER2-positive metastatic breast cancer (MBC) involving the liver and has asymptomatic brain metastases. Which of the following guideline-recommended regimens would you consider as a first-line treatment option for this patient that has demonstrated superior progression-free survival (PFS) compared with taxane plus trastuzumab and pertuzumab (THP), with benefit also observed in patients with baseline brain metastases?

4.

A patient with HER2-positive breast cancer previously received neoadjuvant trastuzumab plus chemotherapy and completed HER2-directed therapy 2 years ago. She now develops metastatic disease. When discussing treatment options, what would you tell this patient about first-line T-DXd plus pertuzumab?